Trafalgar International, Inc. (GCAN)
| Market Cap | 397.55K -1.8% |
| Revenue (ttm) | n/a |
| Net Income | 879.66K |
| EPS | 0.96 |
| Shares Out | 994.38K |
| PE Ratio | 0.42 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,302 |
| Open | 0.3700 |
| Previous Close | n/a |
| Day's Range | 0.3700 - 0.3998 |
| 52-Week Range | 0.0360 - 0.6717 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Trafalgar International
Trafalgar International, Inc. focuses on acquiring, developing and growing businesses in the financial services, technology and intellectual property sectors. The company was formerly known as The Greater Cannabis Company, Inc. and changed its name to Trafalgar International, Inc. in July 2026. The company was founded in 2014 and is based in Miami, Florida. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Trafalgar International Launches U.S. Public Company Platform for Financial Services and Strategic Investment
Company completes Florida name change, advances FINRA corporate action and establishes strategy focused on financial services, technology and intellectual property MEXICO CITY and MIAMI, Aug. 17, 2026...
GCANRx Announces Relisting To OTCQB Market Tier
Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effective ...
GCANRx Announces Uplisting to New Market Tier
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...
GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing
BALTIMORE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generatio...
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoi...
GCANRx Featured in American Journal of Endocannabinoid Medicine
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generati...
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generatio...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...
GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special
The 6 th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19 th at 9pm ET
GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor
Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies.
GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consume...
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products i...
Greater Cannabis Company Announces Retirement of Remaining Convertible Debt
BALTIMORE, MD, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products tod...